Alar Pharmaceuticals

6785.TWO

5.32 USD

0.05

+0.95%

Overview

Last close

5.32 usd

Market cap

355.05M usd

52 week high

14.60 usd

52 week low

3.77 usd

Target price

N/A usd

Valuation

P/E

23.1507

Forward P/E

N/A

Price/Sales

24.0568

Price/Book Value

4.5481

Enterprise Value

276.52M usd

EV/Revenue

12897.4675

EV/EBITDA

19.8018

Key financials

Revenue TTM

14.67M usd

Gross Profit TTM

N/A usd

EBITDA TTM

12.02M usd

Earnings per Share

0.23 usd

Dividend

0.05 usd

Total assets

2.55B usd

Net debt

-676.69M usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.